Evaluation of cardiac activity and pharmacokinetic analysis of 3H-adriamycin in patients pretreated with beta-methyldigoxin

Cancer Chemother Pharmacol. 1979;2(3):169-73. doi: 10.1007/BF00258290.

Abstract

The consequences at the cardiac level of adriamycin treatment alone or in association with the cardiac glycoside beta-methyldigoxin, were evaluated with reference to the PEP/LVET ratio, heart rate, and minimum blood pressure. The variation usually seen in the PEP/LVET ratio when adriamycin is administered alone was not observed when pretreatment with beta-methyldigoxin was also given. A similar situation is found with variations in blood pressure and heart rate. From a pharmacokinetic point of view, this treatment scheme does not seem to affect the general behavior of the antibiotic.

MeSH terms

  • Adult
  • Blood Pressure / drug effects
  • Digoxin / analogs & derivatives*
  • Doxorubicin / metabolism
  • Doxorubicin / pharmacology*
  • Electrocardiography
  • Heart / drug effects*
  • Heart Rate / drug effects
  • Humans
  • Medigoxin / pharmacology*
  • Middle Aged
  • Models, Biological

Substances

  • Digoxin
  • Doxorubicin
  • Medigoxin